CN Bio Raises $21M to Expand Product Portfolio and Support Global Expansion

CN Bio Raises $21M in First Close of Series B Round

CN Bio Raises $21M in Series B Funding

Key Highlights:

  • Series B Funding: CN Bio, a provider of microphysiological systems, raised $21 million in the first close of its Series B funding.
  • New Investors: Funding includes $10 million from Bayland Capital and $5.5 million from founding shareholder CN Innovations Holdings Ltd.
  • Product Portfolio Expansion: Funds will be used to accelerate the development of CN Bio's product portfolio and support global commercial expansion.

CN Bio's Target Market

  • Pharmaceutical and Biotech Companies: Drug developers and researchers seeking advanced microphysiological systems for preclinical drug discovery and reducing reliance on animal models.
  • Research Institutions: Universities, research centers, and laboratories focused on drug discovery and development.
  • Healthcare Providers: Organizations interested in leveraging microphysiological systems for personalized medicine and precision drug testing.

What CN Bio Needs to Buy

  • Research and Development Partnerships: Collaborations with pharmaceutical companies and research institutions for advancing microphysiological systems and drug discovery technologies.
  • Manufacturing and Supply Chain Solutions: Partnerships with manufacturers to scale production and ensure reliable supply of microphysiological systems.
  • Marketing and Sales Support: Services to enhance brand presence, market penetration, and customer acquisition in key global markets.